82VS
Pre-seed → Series A
Their stated focus (public profile)
82VS is a venture studio embedded within Alloy Therapeutics that builds capital-efficient, asset-focused drug companies by leveraging Alloy's discovery platforms and services across antibodies, bispecifics, TCR mimics, and genetic medicines. It partners with academics, entrepreneurs, pharma, and VCs to co-build companies from concept to Series A, providing support in strategy, legal services, R&D funding, and partnerships. Portfolio companies pursue treatments in oncology, neurodegeneration, autoimmune disease, ophthalmology, obesity, and more.
Stages: Pre-seed → Series A
Sectors: Life sciences
On file: 9 partners on record
Website: 82vs.com
This perch was compiled from public sources — filings, the fund’s own site, public write-ups. None of it is the fund’s own words.
Is this your fund? Request a correction or removal.
Search the funds we have on file
Looking for investors? Search the funds we have on file — what they back, where they are, and whether your raise fits. Sign in and Percy matches you to the right ones.
Looking to claim your own fund? Start here →
This perch was compiled from public sources — filings, the fund’s own site, public write-ups. None of it is the fund’s own words.
Funds closest to this thesis
Ordered by how close each thesis sits to this one.
Is this your fund? Request a correction or removal.